Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391727 | 0.92 | ALDH1A1 (0.49) | ADRA1DADRA1AADRA1BSLC18A3TAAR1 | |
| SCHEMBL8231916 | 0.86 | SLC18A3 (0.60) | SLC18A3TSHRKDM4EMEN1KMT2A | |
| SCHEMBL19043430 | 0.84 | GAA (0.45) | HRH3TAAR1KDM4EKMT2A | |
| SCHEMBL13493065 | 0.84 | GAA (0.45) | HRH3TAAR1KDM4EKMT2A | |
| SCHEMBL13108574 | 0.84 | GAA (0.45) | HRH3TAAR1KDM4EKMT2A | |
| SCHEMBL13957316 | 0.82 | LTA4H (0.47) | HRH3SLC18A3KDM4EKMT2A | |
| SCHEMBL5918372 | 0.82 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BSLC18A3TAAR1 | |
| SCHEMBL5918375 | 0.82 | ADRA1D (0.46) | HRH3ADRA1DADRA1AADRA1BSLC18A3 | |
| SCHEMBL6265377 | 0.81 | HTR1A (0.52) | ADRA1DADRA1AADRA1BTAAR1CALM1 | |
| SCHEMBL20689718 | 0.81 | ADRA1D (0.65) | ADRA1DADRA1AADRA1BTAAR1CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475373-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | CACNG5, GRIK5, KCNB1 | HRH3 250/4885ADRA1D 260/4885ADRA1A 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.